RecruitingLung Non-Small Cell Carcinoma
Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study evaluates patient satisfaction with receiving intravenous (IV) and/or subcutaneous (SC) immunotherapy and to assess patient preference for IV immunotherapy administration versus SC immunotherapy administration either at the hospital or at home.
Sponsor: University of Southern California
You may qualify if…
- ✓ \* Age ≥ 18 years.
- ✓ \* Patients must have histopathologically/cytologically confirmed non-small cell lung cancer, currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab (i.e. the patient has already received at least one cycle of therapy)
- ✓ \* Previous chemotherapy/radiotherapy/targeted/immunotherapy is allowed at any prior timepoint.
- ✓ \* Ability to understand and the willingness to sign a written informed consent or presence of a surrogate decision maker who can give consent.
You may not qualify if…
- ✕ \* Patients is unable to consent for themselves
- ✕ \* Patient has not yet completed the 1st cycle of ICI-based therapy
Where it's recruiting
California
Los Angeles
Source: ClinicalTrials.gov · NCT07339254 · last updated 2026-03-16